What's hot
View all perspectives
Jiha Lee JihaRheum
10 months ago
Multimorbidity reduces response to b/tsDMARDs in RA. We can make a difference by treating the whole person!
Amazing talk by Dr Iain McInned to wrap up #ACR24 #ReviewCourse.
@RheumNow https://t.co/NiaUXzt4nT
Mrinalini Dey DrMiniDey
10 months ago
⭐️Top tip from Dr Laura Carbone:
🦴Rule out hypophosphatasia before starting bisphosphonate or denosumab in patients with low ALP
#ACR24 @RheumNow
Brian Jaros, MD Dr_Brian_MD
10 months ago
Pain in PsA = predictor of disability and QoL
TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated biomarkers vs PBO
@RheumNow #ACR24 Abstract #2366 https://t.co/DAgmdmmTE0
Eric Dein ericdeinmd
10 months ago
Risk for atypical femoral fracture:
🚨Asian race - 4-6x higher risk
Duration of use is greater risk than older age
Higher risk when given for osteoporosis than cancer treatment
- Compare: osteonecrosis of jaw more common with cancer Rx
#ACR24 Review Course
@RheumNow https://t.co/V8cD5QWNGp
Dr. John Cush RheumNow
10 months ago
Study of 237 SLE pts shows mood disorders, fibromyalgia & chronic damage were major determinants of poorer Quality of life in SLE. mean SLEDAI-2k was 1.7, 29% had FM; 44% had chronic damage. https://t.co/JHzmleVMIK https://t.co/Sqk9K6oA7M
TheDaoIndex KDAO2011
10 months ago
Don’t use ‘biopsy-proven’ to label sarcoidosis; use ‘biopsy supported’ as there are many causes of granulomatous inflammation. It’s happened to one of my pts who was diagnosed with “biopsy-proven” sarcoidosis - she actually had CVID with GLILD. #ACRReview #ACR24 https://t.co/it41va1K6g
Antoni Chan MD (Prof) synovialjoints
10 months ago
Summary of treatments in psoriatic arthritis #PsA @RheumNow #ACR24 https://t.co/EybzRCPLtA
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.
An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.
Poster Hall